C反应蛋白指导来金鲁单抗早期治疗COVID-19:LIVE-AIR随机三期试验结果
LIVE-AIR三期试验的亚组分析评估基线CRP对来金鲁单抗疗效的指导价值。住院低氧COVID-19患者520例随机接受来金鲁单抗或安慰剂。基线CRP<150 mg/L者来金鲁单抗显著提高28天无通气生存率(HR 2.54),CRP≥150 mg/L者无获益,CRP与治疗交互作用显著。
要点
- 基线CRP<150 mg/L的住院低氧COVID-19患者从来金鲁单抗治疗中获益最大
- CRP≥150 mg/L患者来金鲁单抗无显著获益,CRP与治疗存在显著交互作用
- 来金鲁单抗≥3级不良事件与安慰剂相当,无治疗相关严重不良事件
核心结论
- 基线CRP<150 mg/L的住院低氧COVID-19患者从来金鲁单抗治疗中获得最大临床获益。
研究设计与样本
- 随机、盲法、对照的LIVE-AIR三期试验的亚组分析,来金鲁单抗或安慰剂于第0天给药,随访至第28天。
- 纳入住院COVID-19患者520例,室内空气SpO2≤94%或需补充氧疗但不需有创机械通气。
- 来金鲁单抗1800 mg分三次每8小时给药,24小时内完成,联合皮质类固醇和瑞德西韦治疗。
主要发现
- 基线CRP<150 mg/L者中来金鲁单抗组152例(90%;95%CI 85至94)和安慰剂组144例(79%;72至84)实现SWOV(HR 2.54;95%CI 1.46至4.41;p=0.0009)。
- 基线CRP≥150 mg/L者中来金鲁单抗与安慰剂SWOV无显著差异(HR 1.04;95%CI 0.51至2.14;p=0.9058)。
- 观察到CRP与来金鲁单抗治疗间有统计学显著交互作用(p=0.044)。
- 来金鲁单抗组≥3级不良事件在两个CRP分层中与安慰剂相当,无归因于来金鲁单抗的治疗中出现严重不良事件。
关键数值与推荐
- 主要终点为第28天SWOV的时间至事件分析差异,按基线CRP分层。
- 基线CRP<150 mg/L者来金鲁单抗组SWOV为90%(95%CI 85至94),安慰剂组为79%(72至84),HR 2.54(95%CI 1.46至4.41;p=0.0009)。
- 基线CRP≥150 mg/L者HR 1.04(95%CI 0.51至2.14;p=0.9058)。
- CRP与治疗交互作用p=0.044。
临床怎么用
- 对住院低氧COVID-19患者,基线CRP<150 mg/L可考虑使用来金鲁单抗以提高无通气生存率。
- 基线CRP≥150 mg/L患者来金鲁单抗未见显著获益,需权衡后决策。
局限性
- 本文为LIVE-AIR试验的亚组分析,按基线CRP分层,非预设主要分析。
- 原文未报告亚组样本量、具体P值以外的统计细节及其他潜在局限。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: COVID-19 severity is correlated with granulocyte macrophage colony-stimulating factor (GM-CSF) and C reactive protein (CRP) levels. In the phase three LIVE-AIR trial, lenzilumab an anti-GM-CSF monoclonal antibody, improved the likelihood of survival without ventilation (SWOV) in COVID-19, with the greatest effect in participants having baseline CRP below a median of 79 mg/L. Herein, the utility of baseline CRP to guide lenzilumab treatment was assessed. DESIGN: A subanalysis of the randomised, blinded, controlled, LIVE-AIR trial in which lenzilumab or placebo was administered on day 0 and participants were followed through Day 28. PARTICIPANTS: Hospitalised COVID-19 participants (N=520) with SpO2 ≤94% on room air or requiring supplemental oxygen but not invasive mechanical ventilation. INTERVENTIONS: Lenzilumab (1800 mg; three divided doses, q8h, within 24 hours) or placebo infusion alongside corticosteroid and remdesivir treatments. MAIN OUTCOME MEASURES: The primary endpoint was the time-to-event analysis difference in SWOV through day 28 between lenzilumab and placebo treatments, stratified by baseline CRP. RESULTS: SWOV was achieved in 152 (90%; 95% CI 85 to 94) lenzilumab and 144 (79%; 72 to 84) placebo-treated participants with baseline CRP <150 mg/L (HR: 2.54; 95% CI 1.46 to 4.41; p=0.0009) but not with CRP ≥150 mg/L (HR: 1.04; 95% CI 0.51 to 2.14; p=0.9058). A statistically significant interaction between CRP and lenzilumab treatment was observed (p=0.044). Grade ≥3 adverse events with lenzilumab were comparable to placebo in both CRP strata. No treatment-emergent serious adverse events were attributed to lenzilumab. CONCLUSION: Hospitalised hypoxemic patients with COVID-19 with baseline CRP <150 mg/L derived the greatest clinical benefit from treatment with lenzilumab. TRIAL REGISTRATION NUMBER: NCT04351152; ClinicalTrials.gov.
引用
- Temesgen Z, Kelley CF, Cerasoli F, et al. C reactive protein utilisation, a biomarker for early COVID-19 treatment, improves lenzilumab efficacy: results from the randomised phase 3 'LIVE-AIR' trial. Thorax. 2022. PMID: 35793833. doi:10.1136/thoraxjnl-2022-218744
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。